TW202504613A - 具有Nrf2活化作用之含氮雜環化合物的結晶 - Google Patents

具有Nrf2活化作用之含氮雜環化合物的結晶 Download PDF

Info

Publication number
TW202504613A
TW202504613A TW113122470A TW113122470A TW202504613A TW 202504613 A TW202504613 A TW 202504613A TW 113122470 A TW113122470 A TW 113122470A TW 113122470 A TW113122470 A TW 113122470A TW 202504613 A TW202504613 A TW 202504613A
Authority
TW
Taiwan
Prior art keywords
crystals
crystal
compound
powder
diffraction
Prior art date
Application number
TW113122470A
Other languages
English (en)
Chinese (zh)
Inventor
岩田智哉
髙田則幸
河野将人
Original Assignee
日商中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中外製藥股份有限公司 filed Critical 日商中外製藥股份有限公司
Publication of TW202504613A publication Critical patent/TW202504613A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
TW113122470A 2023-06-19 2024-06-18 具有Nrf2活化作用之含氮雜環化合物的結晶 TW202504613A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023100075 2023-06-19
JP2023-100075 2023-06-19

Publications (1)

Publication Number Publication Date
TW202504613A true TW202504613A (zh) 2025-02-01

Family

ID=93935419

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113122470A TW202504613A (zh) 2023-06-19 2024-06-18 具有Nrf2活化作用之含氮雜環化合物的結晶

Country Status (9)

Country Link
EP (1) EP4696692A1 (cg-RX-API-DMAC7.html)
JP (1) JP7904995B2 (cg-RX-API-DMAC7.html)
KR (1) KR20260023529A (cg-RX-API-DMAC7.html)
CN (1) CN121152792A (cg-RX-API-DMAC7.html)
AU (1) AU2024314540A1 (cg-RX-API-DMAC7.html)
IL (1) IL324833A (cg-RX-API-DMAC7.html)
MX (1) MX2025014082A (cg-RX-API-DMAC7.html)
TW (1) TW202504613A (cg-RX-API-DMAC7.html)
WO (1) WO2024262491A1 (cg-RX-API-DMAC7.html)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
US20190380992A1 (en) 2014-12-04 2019-12-19 Biogen Ma Inc. Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate
JP2020097526A (ja) * 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
KR102932313B1 (ko) 2019-02-15 2026-02-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 활성화제로서 히드록시피리드옥사제핀
CN114174289B (zh) 2019-05-31 2025-03-07 Ube株式会社 苯并三唑衍生物
GB202005852D0 (en) 2020-04-22 2020-06-03 C4X Discovery Ltd Therapeutic compounds
CN114507181B (zh) 2020-11-17 2024-03-26 中国医学科学院药物研究所 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用
CR20240325A (es) 2022-01-07 2024-11-22 Chugai Pharmaceutical Co Ltd Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2

Also Published As

Publication number Publication date
JP7904995B2 (ja) 2026-08-13
IL324833A (en) 2026-01-01
MX2025014082A (es) 2026-01-07
AU2024314540A1 (en) 2025-11-27
KR20260023529A (ko) 2026-02-20
EP4696692A1 (en) 2026-02-18
JPWO2024262491A1 (cg-RX-API-DMAC7.html) 2024-12-26
CN121152792A (zh) 2025-12-16
WO2024262491A1 (ja) 2024-12-26

Similar Documents

Publication Publication Date Title
TWI923765B (zh) 異喹啉酮類化合物及其用途
CN103694236B (zh) 一种嘧啶骨架具有刺猬通路拮抗剂活性的抗肿瘤化合物
TWI778038B (zh) 雜環化合物
CN114685488A (zh) 作为sos1抑制剂的化合物及其应用
CN100528841C (zh) 磺酰胺化合物
ES2991287T3 (es) Compuestos derivados del 1,3,4-oxadiazol como inhibidor de la histona 6 desacetilasa, y la composición farmacéutica que comprende los mismos
CA2910508A1 (en) Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
TW200815398A (en) A novel indazole derivative having spirocyclic structure in the side chain
CN102105464A (zh) Wnt蛋白信号转导抑制剂
WO2020001420A1 (zh) 一类细胞坏死抑制剂及其制备方法和用途
WO2001060803A1 (en) Fused imidazolium derivatives
JPWO2016208576A1 (ja) (6S,9aS)−N−ベンジル−6−[(4−ヒドロキシフェニル)メチル]−4,7−ジオキソ−8−({6−[3−(ピペラジン−1−イル)アゼチジン−1−イル]ピリジン−2−イル}メチル)−2−(プロプ−2−エン−1−イル)−オクタヒドロ−1H−ピラジノ[2,1−c][1,2,4]トリアジン−1−カルボキサミド化合物の結晶
JP7720661B2 (ja) ベンゾ[b]セレノフェン系STING調節剤、その製造方法及び使用
CN112020494A (zh) 用作tlr2信号转导调节剂的化合物
CN108727295A (zh) 一种2-(3-氨基苯基)-苯并噻唑衍生物及其制备方法和用途
AU2018340505A1 (en) Novel heterocyclic compounds as modulators of mGluR7
WO2016104630A1 (ja) 縮合複素環化合物
CN115677664A (zh) 作为parp7抑制剂的哒嗪酮类化合物
WO2024012409A1 (zh) 作为myt1抑制剂的化合物
CN102757448B (zh) 大环类激酶抑制剂化合物、制备方法及其作为药物的应用
CN104334528A (zh) (2-杂芳基氨基)琥珀酸衍生物
JP2013512216A (ja) 置換ピラゾロピリミジン類の結晶形
CN103373986B (zh) 克里唑替尼前药及其制备方法与用途
ES2866324T3 (es) Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria
WO2024262491A1 (ja) Nrf2活性化作用を有する含窒素複素環化合物の結晶